GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have earned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $6.55.

GDRX has been the topic of several recent research reports. Truist Financial decreased their price target on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a research report on Thursday, April 10th. The Goldman Sachs Group decreased their target price on GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. UBS Group dropped their price objective on GoodRx from $6.00 to $5.25 and set a “neutral” rating for the company in a report on Tuesday, May 13th. Finally, Wells Fargo & Company dropped their price objective on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th.

GoodRx Stock Up 0.5%

GDRX stock opened at $3.97 on Wednesday. The stock has a market cap of $1.42 billion, a PE ratio of -132.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.24. The firm’s 50-day simple moving average is $4.42 and its 200 day simple moving average is $4.63. GoodRx has a fifty-two week low of $3.68 and a fifty-two week high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The firm had revenue of $202.97 million during the quarter, compared to analysts’ expectations of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. GoodRx’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.08 EPS. As a group, sell-side analysts predict that GoodRx will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. 8 Knots Management LLC bought a new stake in shares of GoodRx during the 1st quarter worth $8,106,000. Clearbridge Investments LLC purchased a new position in GoodRx during the fourth quarter worth about $5,863,000. EVR Research LP raised its position in GoodRx by 243.3% in the first quarter. EVR Research LP now owns 1,300,000 shares of the company’s stock worth $5,733,000 after acquiring an additional 921,337 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of GoodRx by 303.3% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company’s stock valued at $4,936,000 after buying an additional 798,261 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in GoodRx during the 4th quarter worth approximately $2,500,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.